Your session is about to expire
← Back to Search
This trial is testing a new treatment for melanoma that involves a combination of two drugs. The study is open to people with operable melanoma who have not yet received treatment.
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Side effects dataFrom 2022 Phase 3 trial • 541 Patients • NCT02041533
Awards & Highlights
Find a Location
Who is running the clinical trial?
- You have a previous diagnosis of a lung disease called interstitial lung disease.Your organs are not functioning well enough according to the study's guidelines.You can join this study if you have either recently been diagnosed with melanoma that has spread to nearby lymph nodes or other areas of the body, or if you have had a previous diagnosis of melanoma and it has come back in lymph nodes or other areas.You are able to receive treatment through electroporation.You have a very strong allergic reaction (Grade 3 or higher) to nivolumab or any of its ingredients.You have a history of lung inflammation (not caused by an infection) that required treatment with steroids, or you currently have lung inflammation.You have already received a type of immunotherapy called anti-PD1 or anti-PDL1.If you have cancer that has spread to the skin, soft tissues, or lymph nodes, you may still be eligible if the doctors believe it can be removed with surgery.
- Group 1: Neoadjuvant Treatment
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Could you elucidate on the academic research that has utilized Nivolumab?
"Presently, there are 82 Phase 3 trials for Nivolumab with 718 studies in total. The majority of these investigations take place in Basel, BE; however, globally 40237 sites are executing rigorous clinical research on this drug."
Is this a pioneering clinical trial?
"According to current records, there are 718 Nivolumab studies taking place in 49 countries and 2354 cities. The initial trial for the drug began back in 2012 and was sponsored by Ono Pharmaceutical Co. Ltd. It had 659 participants who completed its Phase 1 & 2 testing stages successfully; since then 252 further investigations have been carried out."
To what extent has enrollment been achieved in this clinical research?
"Indeed, the clinicaltrials.gov page lists this medical trial as actively recruiting participants since its initial post on December 22nd 2020 and last update in November 2022. To date, 33 individuals have been invited to join from a single location."
Is this research effort still seeking participants?
"Clinicaltrials.gov confirms that this research is presently seeking participants, having been first posted on December 22nd 2020 and edited as recently as November 3rd 2022."
Has Nivolumab been authorized by the Food and Drug Administration?
"Due to the Phase 2 nature of this trial, there is some evidence that Nivolumab is safe. Thus, our team assigned it a score of 2 out of 3 on Power's scale."
Share this study with friends